Patent law shields retailers from lawsuits—but strips their right to challenge patents
H.R. 7140 — CLEAR Act · Filed by Laurel Lee (R-FL) · 1 cosponsor · Introduced Jan 16, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds a new patent law allowing courts to pause lawsuits against retailers and end users when a manufacturer of the same product is already being sued for patent infringement. The retailer or end user must agree to accept the outcome of the manufacturer's case and waive certain legal defenses. The stay can be lifted if the manufacturer cannot pay damages. This protects retailers and consumers from being dragged into patent disputes over products they did not make.
Why we flagged it
The bill's core mechanism is procedural — it restructures how patent infringement claims flow through the supply chain by staying actions against non-manufacturers. This is a targeted reform of patent litigation practice, not a substantive change to patent rights themselves.
What the text implies
- Patent holders may face pressure to settle with manufacturers earlier, potentially reducing damages awards and shifting settlement leverage downstream.
- Retailers and end users waive all defenses under 35 U.S.C. § 282(b) (including invalidity challenges), meaning they cannot contest the patent's validity even if the manufacturer does — this may reduce overall patent scrutiny.
- The bond/escrow mechanism (§ 299A(c)) creates a new financial burden on retailers/end users if courts doubt the manufacturer's solvency, potentially chilling legitimate retail of products in uncertain patent landscapes.
- Small retailers may lack resources to post bonds or navigate the stay motion process, creating a de facto barrier to selling products in disputed patent areas despite the bill's stated intent to protect them.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary consumers and small retailers benefit by being shielded from patent litigation costs and complexity when they are not the product makers. The bill reduces frivolous downstream litigation while preserving patent holders' ability to sue the actual manufacturer, balancing innovation incentives against litigation abuse.
Who stands to gain
- retailers and end users (reduced litigation exposure)
- manufacturers (consolidated litigation, reduced downstream claims)
Named in the bill
U.S. Patent and Trademark Office, Federal courts, retailers, end users, manufacturers, patent holders
Where it stands
1 cosponsor: 1 Democrats.
- Jan 16, 2026 — Introduced · Congress.gov: “Introduced in House”
- Jan 16, 2026 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
4 lobbying clients named this bill on 9 disclosure filings across 4 quarters, Dec 2025 to Sep 2026. Those filings disclosed $6,073,941 in lobbying spend. A filing names 30 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 66% of bills with at least one filing.
Laurel Lee, the sponsor, reported $986,500 in PAC receipts in the 2026 cycle.
- Software & Information Industry Association — $5,533,941 on 4 filings
- Pharmaceutical Research & Manufacturers of America Inc — $450,000 on 1 filing
- United for Patent Reform — $60,000 on 1 filing
- American Intellectual Property Law Association (aipla) — $30,000 on 3 filings
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,225 characters) on Nov 13, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.
- H.R. 7140 on Congress.gov
- Actions and status history
- Cosponsors (1)
- Bill text the analysis read
- Software & Information Industry Association — LDA filing, 2026 Q3
- Pharmaceutical Research & Manufacturers of America Inc — LDA filing, 2026 Q1
- United for Patent Reform — LDA filing, 2026 Q3
- Laurel Lee — FEC candidate receipts, 2026 cycle
“Patent law shields retailers from lawsuits—but strips their right to challenge patents” QuorumCivic. https://share.quorumcivic.app/bill/119/hr7140 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.